Category: Cellular Technologies
Multiplex technology, based on the Luminex platform, has evolved into a powerful tool on many fronts to make a direct impact on today’s research targets via dissecting and interrogating many biological pathways. At Abbvie, multiplex technology has delivered data on lead compounds as well as target-based mechanistic insight to many avenues of research such as: 1) to provide gene expression profiling data, which utilizes branched DNA technology, for the weekly turnaround of lead compound efficacy in a number of models, including a mouse IL23 in vivo model, reflective of human psoriasis, across a myriad of gene panels in this pathway for go/no-go decisions to advance compounds; 2) to provide PK/PD information on lead compounds in the stress response pathway when a disease-relevant preclinical model is unavailable; 3) to provide efficacy on lead compounds for pharmacological engagement and modulation as well as insight on disease progression from transgenic models, preclinical models or from clinical samples when available; 4) to provide toxicity evaluation on lead compound series from cardiovascular or renal markers; 5) to provide biomarker support at both the gene and protein level for efficacy and target engagement in the disease state from various sample sources both pre-clinically and clinically; and finally 6) as a powerful tool to provide insight on identification of new target leads from a phenotypic screen investigating the IL17 signaling pathway. This poster will highlight several of these examples to give an overview of the power of multiplexing technology with fast turnaround of critical data.
All authors are employees of AbbVie. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.
Diana Donnelly-Roberts– Principle Research Scientist, AbbVie, North Chicago, IL